These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 17931151)

  • 21. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.
    Bernstein DI; Edwards KM; Dekker CL; Belshe R; Talbot HK; Graham IL; Noah DL; He F; Hill H
    J Infect Dis; 2008 Mar; 197(5):667-75. PubMed ID: 18260764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.
    Puig Barberà J; González Vidal D
    Expert Rev Vaccines; 2007 Oct; 6(5):659-65. PubMed ID: 17931147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
    Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
    Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D
    J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
    de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
    Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study.
    Della Cioppa G; Vesikari T; Sokal E; Lindert K; Nicolay U
    Vaccine; 2011 Nov; 29(47):8696-704. PubMed ID: 21906647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.
    Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli G; Groth N; Del Giudice G
    Hum Vaccin Immunother; 2012 Feb; 8(2):216-27. PubMed ID: 22426371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.
    Esposito S; Pugni L; Daleno C; Ronchi A; Valzano A; Serra D; Mosca F; Principi N
    Pediatrics; 2011 May; 127(5):e1161-8. PubMed ID: 21464195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influenza vaccine with squalene adjuvant: new preparation. No better than available products.
    Prescrire Int; 2004 Dec; 13(74):206-8. PubMed ID: 15599987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine.
    Podda A
    Vaccine; 2001 Mar; 19(17-19):2673-80. PubMed ID: 11257408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.
    Vesikari T; Karvonen A; Tilman S; Borkowski A; Montomoli E; Banzhoff A; Clemens R
    Pediatrics; 2010 Oct; 126(4):e762-70. PubMed ID: 20819892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oil-in-water emulsion adjuvant with influenza vaccine in young children.
    Vesikari T; Knuf M; Wutzler P; Karvonen A; Kieninger-Baum D; Schmitt HJ; Baehner F; Borkowski A; Tsai TF; Clemens R
    N Engl J Med; 2011 Oct; 365(15):1406-16. PubMed ID: 21995388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells.
    Bencharitiwong R; Leonard S; Tsai T; Nowak-Węgrzyn A
    Hum Vaccin Immunother; 2012 Jul; 8(7):863-5. PubMed ID: 22777093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice.
    Cataldo DM; Van Nest G
    Vaccine; 1997 Nov; 15(16):1710-5. PubMed ID: 9364672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of MF59 adjuvant.
    Schultze V; D'Agosto V; Wack A; Novicki D; Zorn J; Hennig R
    Vaccine; 2008 Jun; 26(26):3209-22. PubMed ID: 18462843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.
    Del Giudice G; Hilbert AK; Bugarini R; Minutello A; Popova O; Toneatto D; Schoendorf I; Borkowski A; Rappuoli R; Podda A
    Vaccine; 2006 Apr; 24(16):3063-5. PubMed ID: 16464520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.
    Wack A; Baudner BC; Hilbert AK; Manini I; Nuti S; Tavarini S; Scheffczik H; Ugozzoli M; Singh M; Kazzaz J; Montomoli E; Del Giudice G; Rappuoli R; O'Hagan DT
    Vaccine; 2008 Jan; 26(4):552-61. PubMed ID: 18162266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system.
    Puig-Barberà J; Natividad-Sancho A; Calabuig-Pérez J; Lluch-Rodrigo JA; Pastor-Villalba E; Martínez-Úbeda S; Pérez-Vilar S; Díez-Domingo J
    Vaccine; 2013 Aug; 31(37):3995-4002. PubMed ID: 23731629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals.
    Kajaste-Rudnitski A; Galli L; Nozza S; Tambussi G; Di Pietro A; Pellicciotta G; Monti A; Mascagni P; Moro M; Vicenzi E
    AIDS; 2011 Jan; 25(2):177-83. PubMed ID: 21150561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
    Ruf BR; Colberg K; Frick M; Preusche A
    Infection; 2004 Aug; 32(4):191-8. PubMed ID: 15293073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.